Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CSPC Starts China Trial of Lymphoma Treatment

publication date: Jan 31, 2020

CSPC Pharma has begun a China bridging trial of Copiktra® (duvelisib) in patients with relapsed or refractory follicular lymphoma. Copiktra is an oral inhibitor of phosphoinositide 3-kinase (PI3K). It was approved in 2018 in the US to treat adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Copiktra is the first approved dual inhibitor of PI3K-delta and PI3K-gamma in the US. CSPC, a Shijiazhuang, Hebei Province company that makes novel and generic drugs, in-licensed China rights to Copiktra from Boston's Verastem in 2018. More details....

Stock Symbol: (HK: 1093) (NSDQ: VSTM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.